Nuria Roxana Botticello-Romero

Nuria Roxana Botticello-Romero

Auto-generated profile, based on publicly available information

Nuria Roxana Botticello-Romero

New England Inflammation and Tissue Protection Institute, Department of Pharmaceutical Sciences, Bouvè College of Health Sciences, Northeastern University, Boston, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2024 in Science
Verified
Journal Article
Closed access
QHQin Huang
Qin Huang
KCKen Y. Chan
Ken Y. Chan
JWJason Wu
Jason Wu
NBNuria R. Botticello-Romero
Nuria R. Botticello-Romero
QZQingxia Zheng
Qingxia Zheng
BDBenjamin E. Deverman
Benjamin E. Deverman
Developing vehicles that efficiently deliver genes throughout the human central nervous system (CNS) will broaden the range of treatable genetic diseases. We engineered an adeno-associated virus (AAV) capsid, BI-hTFR1, that binds human transferrin receptor (TfR1), a protein expressed on the blood-brain barrier. BI-hTFR1 was actively transported across human brain endothelial cells and, relative to AAV9, provided 40 to 50 times greater reporter expression in the CNS of human TFRC knockin mice. The enhanced tropism was CNS-specific and absent in wild-type mice. When used to deliver GBA1 , mutations of which cause Gaucher disease and are linked to Parkinson’s disease, BI-hTFR1 substantially increased brain and cerebrospinal fluid glucocerebrosidase activity compared with AAV9. These findings establish BI-hTFR1 as a potential vector for human CNS gene therapy.

23 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
RMRyan Murray
Ryan Murray
MCMD. Raihan Chowdhury
MD. Raihan Chowdhury
NBNuria Roxana Botticello-Romero
Nuria Roxana Botticello-Romero
KDKashvi Desai
Kashvi Desai
SCShanmuga Reddy Chilakapati
Shanmuga Reddy Chilakapati
SHStephen M. Hatfield
Stephen M. Hatfield
Chimeric Antigen Receptor (CAR) T cells have induced remarkable clinical responses in patients with hematological cancers. However, CAR T-cell therapies against solid tumors have not elicited similar outcomes since immunosuppressive barriers in the tumor microenvironment attenuate anti-tumor activity. Here, we describe a multifaceted approach to engineer allogeneic CAR T-cells resistant to both biochemical (hypoxia-adenosinergic) and immunological (PD-L1 and TGF-β) inhibitory signaling using an adenine base editor and a CRISPR-Cas12b nuclease. The resulting EGFR-targeting CAR T-cell product comprised a combination of six gene edits designed to evade allorejection (B2M, CIITA), prevent graft-versus-host disease (CD3E) and overcome biochemical (ADORA2A) and immunological (PDCD1, TGFBR2) barriers in solid tumor microenvironment of subcutaneously grown EGFR+ human lung tumor xenografts. This combinatorial genetic disruption enhances CAR T cell effector function and anti-tumor efficacy leading to improved tumor elimination and survival in xenograft and humanized mouse solid tumor models. Our strategy confers CAR T cells resistance to multiple clinically relevant inhibitory signaling pathways that are amplified in hypoxic tumor areas and may improve the therapeutic potential of CAR T-cells against solid tumors.